Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, February 05, 2020
Catalent has agreed to acquire MaSTherCell Global for an aggregate of $315 million in cash, subject to a customary adjustments.
read more
Catalent and Paragon Bioservices announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion.
read more
Wednesday, September 14, 2016
Catalent has announced an agreement for Catalent, through its wholly owned subsidiary, Catalent Pharma Solutions, Inc., to acquire Pharmatek Laboratories, Inc., a West Coast, U.S.-based specialist in drug development and clinical manufacturing.
read more
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that it has reached an agreement to acquire ...
read more
Friday, September 11, 2020
Catalent is investing $130 million to add five additional Phase 3 through commercial-scale manufacturing suites to its gene therapy campus in Maryland.
read more
Wednesday, January 22, 2025
Catalent, Inc. announced a strategic collaboration with Galapagos NV to support decentralized manufacturing for clinical studies of GLPG5101, Galapagos’ investigational CAR-T therapy for relapsed/refractory non-Hodgkin lymphoma (NHL) indications.
read more
Wednesday, January 11, 2017
Catalent Pharma Solutions has announced that it is to evaluate Jupiter Orphan Therapeutics, Inc.’s (JOT) novel formulation of resveratrol, JOTROL, for delivery using Catalent’s R.P. Scherer softgel technology. Under the agreement, Catalent will ...
read more
Friday, December 16, 2022
Catalent announced that it is to establish a new biologics analytical center of excellence in Durham, within North Carolina’s Research Triangle, to offer comprehensive standalone analytical development and testing for biologic drug modalities, ...
read more
Catalent announced a multi-year $350 million investment at its facility in Bloomington, Indiana, to expand biologics drug substance and drug product manufacturing capabilities. The project will serve the industry’s robust biologics pipeline across ...
read more
Wednesday, April 25, 2018
Catalent Pharma Solutions announced it plans to invest $5 million in the creation of a new drug development CoE at its Somerset, New Jersey facility and headquarters.
read more
Catalent is set to launch its new OneBio Suite for the integrated development, manufacturing, and clinical supply of biologic drugs.
read more
Thursday, September 05, 2019
Catalent announced it will invest $9 million in a new clinical supply facility in San Diego, due to open in the summer of 2020.
read more
Wednesday, January 20, 2016
Catalent Pharma Solutions has announced that it is to introduce clinical supply services at its 200,000 sq. ft. cGMP facility in Kakegawa, Japan.
read more
Tuesday, November 13, 2018
Catalent Pharma Solutions announced its plans to invest $2.5 million in a new, second clinical supply facility in Shanghai, China, due to open in early 2019.
read more
Wednesday, December 04, 2019
Catalent has entered into a partnership with Ethicann, a Calgary-based pharmaceutical company using botanically sourced cannabinoid oils to formulate prescription drugs.
read more